2022 scientific symposium highlights for patients: mds and secondary aml pathophysiology
Published 1 year ago • 358 plays • Length 18:41Download video MP4
Download video MP3
Similar videos
-
11:49
2022 scientific symposium highlights for patients: treatments for mds and secondary aml
-
8:11
non transplant treatments for mds & secondary aml (co-chair summary)
-
3:02
highlights in aml and mds from eha 2022
-
6:58
mds and aml biology (co-chair summary)
-
9:29
mds/aml overlap and novel therapies with dr. naval daver
-
4:26
treatments for mds and secondary aml part 1, low-risk mds
-
50:26
mds - aml - 2020 spring virtual conference: when mds becomes aml - for high-risk mds patients
-
1:28
the potential role of emavusertib in patients with mds and aml
-
18:29
aml treatment challenges who, when, and how
-
7:01
immune based therapies for mds and aml
-
1:11
what is the outlook for aml-mrc, taml, and secondary aml?
-
1:13
expanding treatment options for aml to patients with mds
-
24:14
current aml landscape: where do we stand in 2018?
-
3:08
aml highlights from ash 2017
-
2:09
trends in aml and mds at ash 2021
-
1:10
addressing leukemic transformation in mds: ongoing challenges and future outlooks
-
4:50
mds & aml: implications of genetic mutations for management
-
1:07
changing front-line therapy in mds and aml